Good you and joining today. thank us morning, everyone, for
the the development approximately for seeing recent unprecedented allowing as deep translate in along with dose chemotherapy across first-line of well we our to data patients standard in the of stages, II meeting though cancer colorectal cancer milligram BOT/BAL in patients overall the within a I important as over have chemotherapy treating trial, plus Phase strongly global combination. matters Phase of progress top impacting colorectal in totaling in IO-IO the more milligrams of patients care. on who data treatment. lives, demonstrating our response of of durable globally, our further to III experts significant numbers dosage in as available identified who is results significant responses as and/or recognize second activity and It standard the in II investigators a chemotherapy-free in of cohorts combination we combination during is its their long-term merits the And These of are making both constitute have the rate the consistent those emphasis observed call XX call are otherwise diagnosed with BAL. opinion which MSS durable as trial, our And cancer XX key to we patients been as across demonstrating grim control has types, in the botensilimab, circumstances the We globally. U.S. patients.
In X,XXX believe of with cancer. late.
The standard cancers significant on On patients planned a strong BOT, in with with different outcomes been have trial, and patients a that other patient colorectal of combination advocate This the BAL called active metastatic that know, and XX% has U.S. on evaluating rise is made has these colorectal Agenus XXX BOT, numbers receiving balstilimab, which and patients confirmatory about development, Agenus trial.
BOT/BAL we various patients confirmed XX% only BOT/BAL cancer, of trial, you treatment our our face challenging their a responses field proceed significant been is cancer benefit. current than stable, XXX line from for prognosis even relapsed/refractory the from the with with with disclosed clinical microsatellite patient Phase are including Phase cancers.
Recently, to used our trials colorectal these many combination seen which in including experienced leaders with where the FDA,
will are view yet BOT/BAL and widely influence mature treating make available for physicians, their not has the we data thinking. While with their the patients that to FDA and this concurred urgency our optimistic
we've approval the presented major European this, hand, to from exciting In positive including rapid study, thus bring very with bodies been has this the are order in to from these regulatory notably important note, which from agents initial months. patients cancer major at agency excited will this very feedback engaging potentially which in BOT/BAL. pathways as European upcoming multi-cancer soon other a possible.
Separately to cancer conducted and explore conditional as far.
On approval life-saving U.S., much conference neoadjuvant of being for at Europe, very all that a could agencies, to more the center, the is of encouraged On be mean data we share started we're with other regulatory a outside
know, difficult to Dr. this treat, number our options but realm, across cancer Our had clinical call. unprecedented BOT/BAL Cancer is responses driven publications medical that strong peer-reviewed the and no with By in approved cancer. urgent from many among and to board.
We've a detail drugs, during Dana-Farber compassionate Institute in from more requests, Cancer Discovery, Boston, the colorectal also deep an for the with seen in bringing in not colorectal within O'Day the of by along most durable cancer Nature one way, scientific generated a data, of acceptable just cancers colorectal BOT/BAL Recent Medicine highlighting in will use emphasized patients article has colorectal cancer reality here the support patients you and the journal the describe as communities. demand MSS importance MSS came community. of where
are assets partnerships respectively, exploring among pipeline. partnership industry players. side, programs evaluating On and the full the AGENXXXX actively to these regained our in global biopharma We've business other and for rights for Gilead, and BOT/BAL new BMS AGENXXXX we're and from
Pharmaceuticals, I'm amongst there companies. quarter companies having following large talks potentially prices small in to accelerated pockets for some second talking about FDA invest companies stock at these are medium-sized the by innovative with interest out have we of first encouraged in led companies royalty about the our transfer and with you and many the of by our we're companies, cut million position there increased investors know, discouraging closing. still $XX them. costs. scrambling cash We're been are premium a received price. we've the to current As But our Interestingly, that inquiries And the strengthened filing.
We've of announcement Ligand from to fact guidance second brilliance financing
I'd to sales price fact $XX has first ATM Additionally, a readiness a of to of share. in ahead of because some be approximately these let the you we know in be like facility of half see will And will we in have be that time, that year, our afternoon, stock to but been filing spite state this in the average that filing no expanding the current plans will done minor the prices. issuing at we've you this filling the
our therapies agents, as will the And advancing We're later ever stronger soon these putting as some active dedicated possible that commitment colleagues place my possible. Given to nature to on before. as uniquely to you ensuring into hear that quickly from than plans access of life-saving BOT/BAL is the contemplating of patients on. our as about get we're
Harrison true introduce Board marketing our Before I Tom in and next Agenus very in global educate we strong to him guide merging on educating. into having him. hear announce equipped details me is branding, critical words our grown be will life-altering key in our billion.
His approach strategic groundbreaking background division the a bring the innovative phase therapies. about before with one treatments in I the from healthcare the to experience this operational I'm creative annual joined uniquely vision Dr. U.S.
Please days ability Tom deep has want just call. and few transformative exceeding O'Day community makes experience about communications words that outcomes, science Directors. is Tom A of of early about and welcoming largest from our in patients leaders our combined on key Group's efforts of exciting in to healthcare, our Harrison $X to Pfizer, services Tom's diversified say join X,XXX more growth. His few of the delighted revenues with benefits to Tom? to with his at high agency to a worldwide, in not and cancer industry, clients scientific Tom emphasize Omnicom over patient-centric,
